JNJ-69086420 + JNJ-78278343

**JNJ-69086420 + JNJ-78278343** is an investigational combination of two antibody-based drugs under development by Janssen (Johnson & Johnson) for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). - **JNJ-78278343** (also known as pasritamig) is a bispecific antibody designed to simultaneously bind human kallikrein 2 (KLK2) on prostate tumor cells and CD3 on T-cells, redirecting T-cells to kill KLK2-expressing cancer cells. - **JNJ-69086420** is referenced as an investigational agent by Janssen for use in combination therapies in prostate cancer, but detailed mechanism and properties specific to JNJ-69086420 are not publicly disclosed in the searched literature. - Both agents are administered intravenously and are designed to enhance anti-tumor activity by facilitating tumor-directed immune responses. - The combination is not yet approved for clinical use and is being evaluated in early-phase (Phase 1) clinical trials for dosing, safety, and initial signs of efficacy in patients with mCRPC. - Mechanistically, these drugs represent targeted immunotherapy approaches relying on antibody engineering, and the available evidence suggests the principal action is immune cell redirection to cancer, focused on KLK2+ tumors[1][2][5].